MiR-630 targets LMO3 to regulate cell growth and metastasis in lung cancer

American Journal of Translational Research

Volumn 7, Issue 7, 2015, Pages 1271-1279

  Song, Ying Fang ^a   Hong, Jing Fang ^a   Liu, De Ling ^a   Lin, Qing An ^a   Lan, Xiao Peng ^a   Lai, Guo Xiang ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Invasion; LMO3; Migration; MiR 630; Non small cell lung cancer; Proliferation

Indexed keywords

ALPHA SYNUCLEIN; C REACTIVE PROTEIN; CASPASE 3; CURCUMIN; CYCLOOXYGENASE 2; CYTOCHROME P450; GINSENOSIDE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; METHIONINE SULFOXIDE REDUCTASE A; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHINESE MEDICINE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DOPAMINERGIC NERVE CELL; HEREDITY; INFLAMMATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84939524713     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. [1] Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. [2] Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
3. [3] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
4. [4] Hwang HW and Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-780.
5. [5] Ivey KN and Srivastava D. MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell 2010; 7: 36-41.
6. [6] Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
7. [7] Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
8. [8] Zhang B, Pan X, Cobb GP and Anderson TA. Micrornas as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
9. [9] Cui G, Cui M, Li Y, Liang Y, Li W, Guo H and Zhao S. MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol 2014; 35: 8933-7.
10. [10] Larzabal L, de Aberasturi A, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM and Calvo A. TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer 2014; 110: 764-774.
11. [11] Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411: 846-852.
12. [12] Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
13. [13] Mueller DW and Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009; 101: 551-556.
14. [14] Esquela-Kerscher A and Slack FJ. OncomirsmicroRNAs with a role in cancer. Nature Reviews Cancer 2006; 6: 259-269.
15. [15] Chu D, Zhao Z, Li Y, Li J, Zheng J, Wang W, Zhao Q and Ji G. Increased MicroRNA-630 Expression in Gastric Cancer Is Associated with Poor Overall Survival. PLoS One 2014; 9: e90526.
16. [16] Zhao JJ, Chen PJ, Duan RQ, Li KJ, Wang YZ and Li Y. Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 2014; 7: 3318-3323.
17. [17] Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK and Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013; 8: e61015.
18. [18] Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J and O’Driscoll L. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 2014; 13: 71.
19. [19] Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, Sidransky D and Ratovitski E. Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011; 18: 1220-1230.
20. [20] Huang Y, Guerrero-Preston R and Ratovitski EA. Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle 2012; 11: 1247.
21. [21] Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, Wang MY, Hsiao M, Su JL and Kuo ML. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest 2013; 123: 1082-1095.
22. [22] Patnaik SK, Kannisto E, Knudsen S and Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45.
23. [23] Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P and Robert T. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-1803.
24. [24] Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, Okamoto Y, Tokita H, Ohira M and Nakagawara A. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 2005; 65: 4587-4597.
25. [25] Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T and Nakagawara A. LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun 2010; 392: 252-257.
26. [26] Hui L, Ji C, Hui B, Lv T, Ha X, Yang J and Cai W. The oncoprotein LMO3 interacts with calciumand integrin-binding protein CIB. Brain Res 2009; 1265: 24-29.
27. [27] Isogai E, Ohira M, Ozaki T, Oba S, Nakamura Y and Nakagawara A. Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash 1. PLoS One 2011; 6: e19297.